• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Star Equity Holdings Inc. (Amendment)

    6/8/23 4:52:56 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STRR alert in real time by email
    SC 13D/A 1 strreberwein13d-a6082023.htm SC 13D/A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    (Rule 13d-101)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
    § 240.13d-2(a)

    (Amendment No. 6)1

    Star Equity Holdings, Inc.
    (Name of Issuer)

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

    85513Q103
    (CUSIP Number)

    JEFFREY E. EBERWEIN
    53 Forest Avenue, Suite 101
    Old Greenwich, Connecticut 06870
    (203) 489-9500
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    June 8, 2023
    (Date of Event Which Requires Filing of This Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box .

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.


    _______________
    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).




    1
    NAME OF REPORTING PERSON

    JEFFREY E. EBERWEIN
    2CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (a) 
    (b) 
    3SEC USE ONLY
    4
    SOURCE OF FUNDS

    PF, OO
    5CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION

    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH7
    SOLE VOTING POWER

    4,278,598*
    8
    SHARED VOTING POWER

    -0-
    9
    SOLE DISPOSITIVE POWER

    4,278,598*
    10
    SHARED DISPOSITIVE POWER

    -0-
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,278,598*
    12CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    26.30%
    14
    TYPE OF REPORTING PERSON

    IN

    * Includes 1,075,000 Shares underlying the Warrants (as defined herein) that are immediately exercisable.




    The following constitutes Amendment No. 6 to the Schedule 13D filed by the undersigned (the “Amendment No. 6”). This Amendment No. 6 amends the Schedule 13D as specifically set forth herein.
    Item 3.    Source and Amount of Funds or Other Consideration.

    Capitalized terms not defined herein shall have the meanings set forth in the original Schedule 13D. Item 3 is hereby amended and restated to read as follows:
    Of the 4,278,598 Shares deemed beneficially owned by Mr. Eberwein, (i) 1,075,000 Shares and 1,075,000 accompanying warrants for an additional 1,075,000 Shares (the “Warrants”) were acquired directly from the underwriter in an underwritten public offering conducted by the Issuer that closed on January 24, 2022 (the “2022 Public Offering”), (ii) 650,000 Shares were acquired pursuant to that certain Purchase Agreement, (iii) 1,345,238 Shares were acquired via a combination of purchases with personal funds in the open market (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business), of which 500,000 Shares were purchased pursuant to the 10b5-1 2022 Trading Plan, (iv) 89,360 Shares were acquired upon the vesting of certain Restricted Stock Units awarded to Mr. Eberwein in connection with his service as the Executive Chairman of the Issuer’s Board, and (v) 44,000 Shares were acquired in a public offering consummated in May 2020 (the “2020 Public Offering”).
    The aggregate purchase price of the Shares purchased in the open market and in the 2022 Public Offering and 2020 Public Offering is approximately $5,746,383, excluding brokerage commissions. The other Shares were acquired by Mr. Eberwein as described above.
    In addition to the Shares, Mr. Eberwein owns 1,222,458 shares of the Issuer’s 10% Series A Cumulative Perpetual Preferred Stock.
    Item 5.    Interest in Securities of the Issuer.

    Items 5(a)-(c) are hereby amended and restated to read as follows:



    The aggregate percentage of Shares reported owned by the Reporting Person is based upon 15,196,090 Shares outstanding, which is the total number of Shares outstanding based on information provided by the Issuer to the Reporting Person.
    A.    Mr. Eberwein
    (a)    As of the close of business on June 8, 2023, Mr. Eberwein beneficially owned 4,278,598 Shares (including 1,075,000 Shares underlying the Warrants, which are immediately exercisable).
    Percentage: Approximately 26.30%
    (b)    1. Sole power to vote or direct vote: 4,278,598
    2. Shared power to vote or direct vote: 0
    3. Sole power to dispose or direct the disposition: 4,278,598
    4. Shared power to dispose or direct the disposition: 0

    (c)    The transactions in the Shares by the Reporting Person since the filing of Amendment No. 4 the Schedule 13D are set forth in Schedule A and are incorporated herein by reference.

    SIGNATURES

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
    Dated: June 8, 2023

    /s/ Jeffrey E. Eberwein
    JEFFREY E. EBERWEIN

    SCHEDULE A
    Transactions in the Shares Since the Filing of Amendment No. 5 to the Schedule 13D



    Shares of Common Stock
    Purchased/(Sold)
    Price Per
    Share ($)1
    Date of
    Purchase/Sale
    10,000$0.97
    2
    12/16/2022
    8,407$0.99
    3
    12/19/2022
    17,300$0.84
    4
    5/18/2023
    10,647$0.90
    5
    5/19/2023
    39,300$0.93
    6
    5/22/2023
    10,000$0.99
    7
    5/23/2023
    2,500$1.015/25/2023
    14,412$1.05
    8
    6/2/2023
    3,800$1.106/5/2023
    44,954$1.09
    9
    6/6/2023
    40,000$1.10
    10
    6/7/2023
    37,000$1.08
    11
    6/8/2023
    image_0.jpg
    1The prices reported in this column are weighted average prices. Mr. Eberwein undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased (or sold) at each separate price such shares were purchased.
    2These shares were purchased in multiple transactions at prices ranging from $0.94 to $1.00, inclusive.
    3These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.00, inclusive.
    4These shares were purchased in multiple transactions at prices ranging from $0.84 to $0.87, inclusive.
    5These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.92, inclusive.
    6These shares were purchased in multiple transactions at prices ranging from $0.92 to $0.95, inclusive.
    7These shares were purchased in multiple transactions at prices ranging from $0.98 to $0.99, inclusive.
    8These shares were purchased in multiple transactions at prices ranging from $1.05 to $1.06, inclusive.
    9These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive.
    10These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.10, inclusive.
    11These shares were purchased in multiple transactions at prices ranging from $1.06 to $1.09, inclusive.


    Get the next $STRR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STRR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $STRR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Star Equity Holdings, Inc. Announces 2025 Second Quarter Financial Results

    Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million Generated Adjusted EBITDA of $7.0 million Quarter-end Building Solutions backlog stands at $25.7 million OLD GREENWICH, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, reported today its financial results for the second quarter (Q2) ended June 30, 2025. All 2025 and 2024 amounts in this release are unaudited. Q2 2025 Financial Highlights vs. Q2 2024 (unaudited) Revenues increased by 75.8% to $23.7 million from $13.5 million.Gross profit increased by 182.2% to $6.3 million from $2.2 million.

    8/13/25 8:30:29 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Declares a Partial Cash Dividend of $0.225 Per Share of 10% Series A Cumulative Perpetual Preferred Stock

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, announced today that its Board of Directors declared a partial cash dividend to holders of the Company's 10% Series A Cumulative Perpetual Preferred Stock ("Star Preferred Stock") of $0.225 per share. The record date for this dividend is August 21, 2025 and the payment date is September 10, 2025. As previously disclosed, on May 21, 2025, Hudson Global, Inc., a Delaware corporation ("Hudson"), HSON Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Hudson ("Merger Sub"), and the Company, entered into

    8/8/25 5:15:31 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hudson Global Reports 2025 Second Quarter Results

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (NASDAQ:HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Summary Revenue of $35.5 million decreased 0.5% from the second quarter of 2024 and 0.2% in constant currency.Adjusted net revenue of $18.6 million increased 5.8% from the second quarter of 2024 and 5.1% in constant currency.Net loss was $0.7 million, or $0.23 per diluted share, compared to net loss of $0.4 million, or $0.15 per diluted share, for the second quarter of 2024. Adjusted net income per d

    8/8/25 8:30:45 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    SEC Filings

    View All

    Star Equity Holdings Inc. filed SEC Form 8-K: Other Events

    8-K - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/15/25 4:10:33 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Star Equity Holdings Inc.

    10-Q - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/13/25 4:12:57 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - STAR EQUITY HOLDINGS, INC. (0000707388) (Filer)

    8/13/25 8:44:18 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Coleman Richard Kenneth Jr. bought $10,675 worth of shares (2,500 units at $4.27) and bought $4,925 worth of 10% Series A Cumulative Perpetual Preferred Stock (500 units at $9.85), decreasing direct ownership by 93% to 2,500 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/20/24 4:10:35 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Butcher Thatcher bought $3,120 worth of shares (3,000 units at $1.04), increasing direct ownership by 100% to 6,000 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    12/15/23 1:41:36 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Coleman Richard Kenneth Jr. bought $2,220 worth of shares (2,000 units at $1.11) and bought $18,900 worth of 10% Series A Cumulative Perpetual Preferred Stock (2,000 units at $9.45), decreasing direct ownership by 98% to 2,000 units (SEC Form 4)

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    12/4/23 8:25:38 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Financials

    Live finance-specific insights

    View All

    Star Equity Holdings, Inc. Announces 2025 Second Quarter Financial Results

    Q2 2025 revenues increased ~76% to $23.7 million and gross profit increased ~182% to $6.3 million Generated Adjusted EBITDA of $7.0 million Quarter-end Building Solutions backlog stands at $25.7 million OLD GREENWICH, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)) ("Star" or the "Company"), a diversified holding company, reported today its financial results for the second quarter (Q2) ended June 30, 2025. All 2025 and 2024 amounts in this release are unaudited. Q2 2025 Financial Highlights vs. Q2 2024 (unaudited) Revenues increased by 75.8% to $23.7 million from $13.5 million.Gross profit increased by 182.2% to $6.3 million from $2.2 million.

    8/13/25 8:30:29 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hudson Global Reports 2025 Second Quarter Results

    OLD GREENWICH, Conn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hudson Global, Inc. (NASDAQ:HSON) ("Hudson Global" or "the Company"), a leading global total talent solutions company, announced today financial results for the second quarter ended June 30, 2025. 2025 Second Quarter Summary Revenue of $35.5 million decreased 0.5% from the second quarter of 2024 and 0.2% in constant currency.Adjusted net revenue of $18.6 million increased 5.8% from the second quarter of 2024 and 5.1% in constant currency.Net loss was $0.7 million, or $0.23 per diluted share, compared to net loss of $0.4 million, or $0.15 per diluted share, for the second quarter of 2024. Adjusted net income per d

    8/8/25 8:30:45 AM ET
    $HSON
    $STRR
    Professional Services
    Consumer Discretionary
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings to Release Second Quarter 2025 Financial Results on August 13

    OLD GREENWICH, Conn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP)), ("Star Equity" or the "Company"), a diversified holding company, announced today that it will release its financial results for the second quarter ended June 30, 2025, before the market opens on Wednesday, August 13, 2025. A conference call is scheduled for 10:00 a.m. ET (7:00 a.m. PT) on August 13, 2025, to discuss the results and management's outlook. The call may be accessed by dialing: Toll Free: 1-833-630-1956International: 1-412-317-1837 A simultaneous webcast of the call may be accessed online from the Events & Presentations link, on the Investor Relations page of the Star Eq

    8/4/25 8:30:30 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Leadership Updates

    Live Leadership Updates

    View All

    Star Equity Holdings, Inc. Appoints Rick Coleman as CEO

    OLD GREENWICH, Conn., April 01, 2022 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified holding company, announced today the appointment of Richard ("Rick") K. Coleman, Jr. as Chief Executive Officer, effective April 1, 2022. In addition, Mr. Coleman will be nominated to serve as a director at the Company's upcoming annual meeting of shareholders. Mr. Coleman is a seasoned executive who brings to Star Equity extensive CEO leadership and board-level experience with numerous public and private companies. He was appointed as Star Equity's Chief Operating Officer in January 2022 and has provided valuable insights and direction

    4/1/22 8:00:00 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Adds Richard Coleman as Chief Operating Officer

    OLD GREENWICH, Conn., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified holding company, announced today the appointment of Richard K. Coleman, Jr. ("Rick") as Chief Operating Officer, effective January 1, 2022. Coleman's addition increases the capacity of Star Equity's senior leadership team. In this role, he will oversee the Company's operations, assist its business leaders in achieving their growth and profitability goals, launch new business initiatives, as well as help analyze and integrate future acquisitions. Coleman brings more than 30 years of executive leadership experience with extensive expertis

    12/20/21 8:00:00 AM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Star Equity Holdings, Inc. Appoints John Gildea to its Board of Directors

    OLD GREENWICH, Conn., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Star Equity Holdings, Inc. (NASDAQ:STRR, STRRP))) ("Star Equity" or the "Company"), a diversified, multi-industry holding company with three business divisions, Healthcare, Construction, and Investments, announced today the appointment of John W. Gildea to its Board of Directors, effective immediately. Mr. Gildea's appointment as independent director expands Star Equity's Board to six members. Mr. Gildea will also serve on the Audit Committee. Mr. Gildea brings over three decades of experience investing in special situation debt and equity of small to middle market companies. He is the founding partner of Gildea Management Co., a fir

    8/6/21 4:38:13 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Star Equity Holdings Inc.

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    9/10/24 4:04:39 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D/A filed by Star Equity Holdings Inc. (Amendment)

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    9/18/23 4:05:02 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D/A filed by Star Equity Holdings Inc. (Amendment)

    SC 13D/A - STAR EQUITY HOLDINGS, INC. (0000707388) (Subject)

    8/31/23 5:18:25 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $STRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Palmer Jennifer

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:24:27 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Fruhbeis Todd Michael

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:23:28 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Parks Louis A.

    4 - STAR EQUITY HOLDINGS, INC. (0000707388) (Issuer)

    8/18/25 7:22:47 PM ET
    $STRR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care